These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 24477907)

  • 41. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
    Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
    J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
    Fujii S
    Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cancer vaccines for established cancer: how to make them better?
    Andrews DM; Maraskovsky E; Smyth MJ
    Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.
    van Beek JJ; Wimmers F; Hato SV; de Vries IJ; Sköld AE
    Crit Rev Immunol; 2014; 34(6):517-36. PubMed ID: 25597314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
    Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
    Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells.
    Karimi K; Boudreau JE; Fraser K; Liu H; Delanghe J; Gauldie J; Xing Z; Bramson JL; Wan Y
    Mol Ther; 2008 Feb; 16(2):411-8. PubMed ID: 18059374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dendritic cells and cancer immunotherapy.
    Radford KJ; Tullett KM; Lahoud MH
    Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response.
    Morandi B; Mortara L; Chiossone L; Accolla RS; Mingari MC; Moretta L; Moretta A; Ferlazzo G
    PLoS One; 2012; 7(6):e39170. PubMed ID: 22723958
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells.
    Shinagawa N; Yamazaki K; Tamura Y; Imai A; Kikuchi E; Yokouchi H; Hommura F; Oizumi S; Nishimura M
    Cancer Immunol Immunother; 2008 Feb; 57(2):165-74. PubMed ID: 17628800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
    Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
    J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Variable Genomic NK Cell Receptor Locus Is a Key Determinant of CD4+ T Cell Responses During Viral Infection.
    Raynor J; Lin A; Hummel SA; Lampe K; Jordan M; Hoebe K; Hildeman DA
    Front Immunol; 2020; 11():197. PubMed ID: 32153566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.
    Willemen Y; Van den Bergh JM; Lion E; Anguille S; Roelandts VA; Van Acker HH; Heynderickx SD; Stein BM; Peeters M; Figdor CG; Van Tendeloo VF; de Vries IJ; Adema GJ; Berneman ZN; Smits EL
    Cancer Immunol Immunother; 2015 Jul; 64(7):831-42. PubMed ID: 25863943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dendritic cell based tumor vaccines.
    Nouri-Shirazi M; Banchereau J; Fay J; Palucka K
    Immunol Lett; 2000 Sep; 74(1):5-10. PubMed ID: 10996622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
    Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
    J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Uric acid enhances the antitumor immunity of dendritic cell-based vaccine.
    Wang Y; Ma X; Su C; Peng B; Du J; Jia H; Luo M; Fang C; Wei Y
    Sci Rep; 2015 Nov; 5():16427. PubMed ID: 26553557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
    Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
    Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain.
    Prins RM; Vo DD; Khan-Farooqi H; Yang MY; Soto H; Economou JS; Liau LM; Ribas A
    J Immunol; 2006 Dec; 177(12):8448-55. PubMed ID: 17142742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.